Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts

Leukemia Research

Volumn 37, Issue 1, 2013, Pages 64-70

  Maassen, Anna ^a   Strupp, Corinna ^a   Giagounidis, Aristoteles ^b   Kuendgen, Andrea ^a   Nachtkamp, Kathrin ^a   Hildebrandt, Barbara ^a   Gattermann, Norbert ^a   Aul, Carlo ^b   Haas, Rainer ^a   Germing, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ST JOHANNES HOSPITAL   (Germany)

Author keywords

MDS unclassifiable; Myelodysplastic syndromes; RA; RCUD; RN; RT; WHO classification

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH UNILINEAGE DYSPLASIA; REFRACTORY NEUTROPENIA; REFRACTORY THROMBOPENIA; SURVIVAL TIME; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; HUMANS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; WORLD HEALTH ORGANIZATION;

EID: 84870953672     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.09.021     Document Type: Article

References (24)

1. Brunning R.S., Orazi A., Germing U., et al. Myelodysplastic syndromes/neoplasms, overview. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 88-107. IARC Press, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman (Eds.).
2. Germing U., Gattermann N., Strupp C., Aivado M., Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000, 24:983-992.
3. Germing U., Strupp C., Giagounidis A., Haas R., Gattermann N., Starke C., et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. Leuk Res 2012, 36:727-734.
4. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
5. Breccia M., Latagliata R., Cannella L., Carmosino I., Santopietro M., Loglisci G., et al. Refractory cytopenia with unilineage dysplasia: analyses of prognostic factors and survival in 126 patients. Leuk Lymphoma 2010, 51:783-788.
6. Gyan E., Andrieu V., Caille A., Park S., Stamatoullas A., Selosse V., et al. Myelodysplastic syndromes with isolated neutropenia or thrombocytopenia: are they refractory cytopenias with unilineage dysplasia?. Leuk Res 2011, 35(Suppl. 1):S22.
7. Knipp S., Strupp C., Gattermann N., Hildebrandt B., Schapira M., Giagounidis A., et al. Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leuk Res 2008, 32:33-37.
8. Verburgh E., Achten R., Louw V.J., Brusselmans C., Delforge M., Boogaerts M., et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia 2007, 21:668-677.
9. Cazzola M., Invernizzi R., Bergamaschi G., Levi S., Corsi B., Travaglino E., et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003, 101:1996-2000.
10. Boultwood J., Pellagatti A., Nikpour M., Pushkaran B., Fidler C., Cattan H., et al. The role of iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS ONE 2008, 3:e1970.
11. Cavadini P., Biasiotto G., Poli M., Levi S., Verardi R., Zanella I., et al. RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload. Blood 2007, 109:3552-3559.
12. + and in stromal cells in refractory anemia with ringed sideroblasts. BMC Med Genomics 2010, 3:30.
13. Papaemmanuil E., Cazzola M., Boultwood J., Malcovati L., Vyas P., Bowen D., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011, 365:1384-1395.
14. Rosati S., Mick R., Xu F., Stonys E., Le Beau M.M., Larson R., et al. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. Leukemia 1996, 10:20-26.
15. Matsuda A., Jinnai I., Yagasaki F., Kusumoto S., Minamihisamatsu M., Honda S., et al. Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia 1998, 12:482-485.
16. Cermák J., Belicková M., Krejcová H., Michalová K., Zilovcová S., Zemanová Z., et al. The presence of clonal cell populations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia. Leuk Res 2005, 29:371-379.
17. Cermák J., Vítek A., Michalová K. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. Leuk Res 2004, 28:551-557.
18. Giagounidis A.A., Germing U., Haase S., Hildebrandt B., Schlegelberger B., Schoch C., et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004, 18:113-119.
19. Germing U., Strupp C., Kuendgen A., Isa S., Knipp S., Hildebrandt B., et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006, 91:1596-1604.
20. Germing U., Lauseker M., Hildebrandt B., Symeonidis A., Cermak J., Fenaux P., et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia 2012, 26:1286-1292.
21. Jädersten M., Saft L., Smith A., Kulasekararaj A., Pomplun S., Göhring G., et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011, 29:1971-1979.
22. Broseus J., Florensa L., Zipperer E., Schnittger S., Malcovati L., Richebourg S., et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica 2012, [Epub ahead of print].
23. Gattermann N., Billiet J., Kronenwett R., Zipperer E., Germing U., Nollet F., et al. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600×109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 2007, 109:1334-1335.
24. Zipperer E., Wulfert M., Germing U., Haas R., Gattermann N. MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500×10(9)/l. Ann Hematol 2008, 87:413-415.